Regentis Biomaterials Ltd. (RGNT)
NYSEAMERICAN: RGNT · Real-Time Price · USD
3.360
+0.010 (0.30%)
Mar 6, 2026, 4:00 PM EST - Market closed

Regentis Biomaterials Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020
Selling, General & Admin
6.640.711.130.440.33
Upgrade
Research & Development
0.33-1.640.810.970.34
Upgrade
Operating Expenses
6.97-0.931.931.410.67
Upgrade
Operating Income
-6.970.93-1.93-1.41-0.67
Upgrade
Interest Expense
-0.08-0.01---
Upgrade
Currency Exchange Gain (Loss)
0.070.1-0.070.26-0.02
Upgrade
Other Non Operating Income (Expenses)
-6.673.78-2.13-0.3-4.46
Upgrade
Pretax Income
-13.654.8-4.13-1.45-5.14
Upgrade
Net Income
-13.654.8-4.13-1.45-5.14
Upgrade
Preferred Dividends & Other Adjustments
0.044.520.050.050.05
Upgrade
Net Income to Common
-13.690.28-4.18-1.5-5.19
Upgrade
Shares Outstanding (Basic)
10000
Upgrade
Shares Outstanding (Diluted)
10000
Upgrade
Shares Change (YoY)
249.41%-6.52%6.97%--
Upgrade
EPS (Basic)
-24.161.72-24.09-9.23-32.00
Upgrade
EPS (Diluted)
-24.161.72-24.09-9.23-32.00
Upgrade
EBIT
-6.970.93-1.93-1.41-0.67
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.